Yourgene Health PLC - Result of Court Meeting and General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN
FOR IMMEDIATE RELEASE
RECOMMENDED CASH OFFER
for
Yourgene Health plc ("Yourgene")
by
Novacyt UK Holdings Limited ("Novacyt UK")
(a wholly-owned subsidiary of Novacyt S.A. ("Novacyt"))
to be effected by means of a Scheme of Arrangement
under Part 26 of the Companies Act 2006
Result of Court Meeting and General Meeting
On
The Acquisition is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
A circular in relation to the Scheme was published by Yourgene on
The board of Yourgene is pleased to announce that at the Court Meeting and the General Meeting, each convened in accordance with an order of the Court dated
A. the requisite majority of Scheme Shareholders who voted and were entitled to vote (either in person or by proxy), representing not less than 75 per cent. in value of the Scheme Shares held by the Scheme Shareholders who voted, voted in favour of the resolution to approve the Scheme at the Court Meeting; and
B. the requisite majority of Yourgene Shareholders voted to pass the Special Resolution at the General Meeting to approve, inter alia, the implementation of the Scheme, the adoption of amended articles of association for Yourgene and the re-registration of Yourgene as a private limited company and accordingly, the Scheme was approved.
Details of the resolutions passed are set out in the notices of the Court Meeting and the General Meeting at Parts VIII and Part IX (respectively) of the Scheme Document, which is available on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/ and on Novacyt's website at https://novacyt.com/investors/. A copy of the Special Resolution passed at the General Meeting will be submitted today to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The total number of Yourgene Shares in issue at
The detailed voting results in relation to the Court Meeting and the General Meeting are summarised below and this announcement will be posted on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/.
Voting results of the Court Meeting
At the Court Meeting, a majority in number of Scheme Shareholders who voted (either in person or by proxy), representing 98.88 per cent. by value of those Scheme Shares voted, voted in favour of the resolution to approve the Scheme. The resolution proposed at the Court Meeting was passed on a poll vote. Details of the votes cast are as follows:
|
Results of the Court Meeting |
No. of Scheme Shareholders who voted |
% of Scheme Shareholders who voted1 |
No. of Scheme Shares voted |
% of Scheme Shares voted |
No. of Scheme Shares voted as a % of the issued share capital eligible to vote on the Scheme1 |
|
For2 |
70 |
82.35 |
1,848,544,395 |
98.88 |
57.89 |
|
Against |
15 |
17.65 |
21,013,713 |
1.12 |
0.66 |
|
Total |
753 |
- |
1,869,558,108 |
- |
58.54 |
Notes:
1All percentages set out in the table above have been rounded to two decimal places. As a result of such rounding the totals of the percentages presented in these totals may vary slightly from the actual arithmetic totals of such percentages.
2Any proxy appointments which gave discretion to the Chairman have been included in the vote "For" total.
3The total number of Scheme Shareholders voting for and against the resolution exceeds the total number of Scheme Shareholders who voted as 10 Scheme Shareholders gave instructions for votes to be cast in favour of the resolution in respect of part of their holding of Scheme Shares and against the Resolution in respect of another part of their holding of Scheme Shares.
Voting results of the General Meeting
At the General Meeting, the special resolution to, inter alia, authorise the implementation of the Scheme and approve the adoption of the amended articles of association for Yourgene, was duly passed on a poll vote. The results are detailed as follows:
|
Special Resolution |
VOTES FOR2 |
VOTES AGAINST |
TOTAL |
WITHHELD 3 |
||
|
Number of Yourgene Shares voted |
% of Yourgene Shares voted1 |
Number of Yourgene Shares voted |
% of Yourgene Shares voted 1 |
Number |
Number |
|
|
|
1,878,976,167 |
98.00 |
38,426,436 |
2.00 |
1,917,402,603 |
2,931,364 |
Notes:
1All percentages set out in the table above have been rounded to two decimal places. As a result of such rounding the totals of the percentages presented in these totals may vary slightly from the actual arithmetic totals of such percentages.
2Any proxy appointments which gave discretion to the Chairman have been included in the vote "For" total.
3A withheld vote is not a vote in law and, accordingly, is not counted in the calculation of the proportion of votes "For" or "Against" the resolution concerned.
Timetable, Conditions and Scheme Document
The outcome of the Court Meeting and the General Meeting means that Conditions 2.1 and 2.2 (as set out in Part III of the Scheme Document) have been satisfied.
The Acquisition remains subject to the satisfaction or (where applicable) waiver of the remaining Conditions and to the further terms set out in Part III of the Scheme Document, including the Court sanctioning the Scheme at the Court Sanction Hearing and the delivery of a copy of the Court Order to the Registrar of Companies.
The expected timetable of principal events for the implementation of the Scheme remains as set out on page 12 of the Scheme Document and is set out in the appendix to this announcement. The dates are indicative only and are subject to change. The dates will depend, among other things, on the date upon which: (i) the Conditions are satisfied or (if capable of waiver) waived; (ii) the Court sanctions the Scheme; and (iii) a copy of the Court Order is delivered to the Registrar of Companies.
Yourgene will give adequate notice of all of these dates and times, when known, by issuing an announcement through a Regulatory Information Service, with such announcement being made available on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/. Any revisions or changes to these dates and/or times will be notified in the same way.
Enquiries:
|
Yourgene |
|
|
|
c/o Stifel |
|
Stifel (Rule 3 Adviser and Sole Financial Adviser to Yourgene) |
|
|
|
Tel: +44 (0) 20 7710 7600 |
|
Cairn (Nominated Adviser to Yourgene) |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
Walbrook PR Limited (Media and Investor Relations for Yourgene) |
|
|
|
Tel: +44 (0) 20 7933 8780 or yourgene@walbrookpr.com Mob: +44 (0) 7407 804 654 / +44 (0) 7584 391 303 |
|
Novacyt |
|
|
|
c/o Numis |
|
Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK) |
|
|
|
Tel: +44 (0) 20 7260 1000 |
|
S.P. Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt) |
|
|
|
Tel: +44 (0) 20 3470 0470 |
|
Walbrook PR Limited (Media and Investor Relations for Novacyt) |
|
|
|
Tel: +44 (0) 20 7933 8780 or novacyt@walbrookpr.com |
Addleshaw Goddard LLP is providing legal advice to Yourgene.
Stephenson Harwood LLP is providing legal advice to Novacyt and Novacyt UK.
Important Notices
Numis Securities Limited ("Numis"), which is authorised and regulated in the
S.P. Angel Corporate Finance LLP ("SP Angel"), which is authorised and regulated in the
Stifel Nicolaus Europe Limited ("Stifel"), which is authorised and regulated in the
Cairn Financial Advisers LLP ("Cairn"), which is authorised and regulated in the
The statements contained in this announcement are made as at the date of this announcement, unless some other time is specified in relation to them, and service of this announcement shall not give rise to any implication that there has been no change in the facts set forth in this announcement since such date.
Overseas shareholders
The release, publication or distribution of this announcement in or into certain jurisdictions other than the
Unless otherwise determined by Novacyt and Novacyt UK, or required by the Code, and permitted by applicable law and regulation, the Acquisition will not be made available, directly or indirectly, in, into or from a Restricted Jurisdiction where to do so would violate the laws in that jurisdiction and no person may vote in favour of the Acquisition by any such use, means, instrumentality or from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the laws of that jurisdiction. Accordingly, copies of this announcement and all documents relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from a Restricted Jurisdiction where to do so would violate the laws in that jurisdiction, and persons receiving this announcement and all documents relating to the Acquisition (including custodians, nominees and trustees) must observe these restrictions and must not mail or otherwise distribute or send them in, into or from such jurisdictions where to do so would violate the laws in that jurisdiction.
Further details in relation to Yourgene Shareholders in overseas jurisdictions are contained in the Scheme Document.
Yourgene Shareholders in
None of the securities referred to in this announcement, nor the information contained in this announcement, has been approved or disapproved by the U.S. Securities and Exchange Commission, any state securities commission in
Yourgene's financial statements, and all financial information that is included in this announcement or that may be included in the Scheme Document, or any other documents relating to the Acquisition, have been prepared in accordance with International Financial Reporting Standards and may not be comparable to financial statements of companies in
It may be difficult for
If Novacyt UK were to elect to implement the Acquisition by means of a Takeover Offer and determines to extend the Takeover Offer into
The receipt of cash pursuant to the Acquisition by a Yourgene Shareholder in
In accordance with normal
Forward-looking statements
This announcement may contain certain "forward-looking statements" with respect to Yourgene, Novacyt and Novacyt UK. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "will", "may", "should", "would", "could" or other words or terms of similar meaning or the negative thereof. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies of Novacyt and/or Novacyt UK and/or Yourgene and the expansion and growth of the Novacyt Group's and/or the Yourgene Group's operations and potential synergies resulting from the Acquisition; and (iii) the effects of government regulation on the business of the Yourgene Group or the Novacyt Group.
These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or developments to differ materially from those expressed in or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding present and future strategies and environments. None of Novacyt, Novacyt UK or Yourgene, nor any of their respective associates, directors, officers, employees or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur. You are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. All subsequent oral or written forward-looking statements attributable to Novacyt, Novacyt UK or Yourgene or any person acting on their behalf are expressly qualified in their entirety by the cautionary statement above. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement. Novacyt, Novacyt UK and Yourgene assume no obligation to update publicly or revise forward-looking or other statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.
No profit forecasts or estimates
Nothing in this announcement is intended or shall be deemed as a forecast, projection or estimate of the future financial performance of Novacyt, Novacyt UK or Yourgene for any period and no statement in this announcement should be interpreted to mean that cash flow from operations, earnings, earnings per Yourgene Share or Novacyt Share, or income for the current or future financial years would necessarily match or exceed the historical published cash flow from operations, earnings, earnings per Yourgene Share or Novacyt Share or income of Yourgene or Novacyt, as appropriate.
Right to switch to a Takeover Offer
Novacyt UK reserves the right to elect, with the consent of the Takeover Panel, to implement the Acquisition by way of a Takeover Offer as an alternative to the Scheme. In such an event, the Takeover Offer will be implemented on the same terms or, if Novacyt UK so decides, on such other terms being no less favourable (subject to appropriate amendments), so far as applicable, as those which would apply to the Scheme.
Publication on website
In accordance with Rule 26 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions), free of charge, on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/ and on Novacyt's website at https://novacyt.com/investors/ by no later than 12.00 noon on the Business Day following the date of this announcement.
Neither the contents of these websites nor the content of any other website accessible from hyperlinks on such websites is incorporated into, or forms part of, this announcement.
Requesting hard copies
In accordance with Rule 30.3 of the Code, Yourgene Shareholders may request a hard copy of this announcement (and any information incorporated by reference into this announcement), free of charge, by contacting the Yourgene's registrar, Link Group, by: (i) submitting a request in writing to Link Group,
For persons who receive a copy of this announcement in electronic form or via a website notification, a hard copy of this announcement will not be sent unless so requested. Such persons may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.
Information relating to Yourgene Shareholders
Please be aware that addresses, electronic addresses and certain information provided by Yourgene Shareholders, persons with information rights and other relevant persons for the receipt of communications from Yourgene may be provided to Novacyt UK during the Offer Period as required under section 4 of Appendix 4 of the Code.
Rounding
Certain figures included in this announcement have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.
Dealing and Opening Position Disclosure requirements
Under Rule 8.3(a) of the Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than
If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3 of the Code.
Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of the Code).
Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at https://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +44 (0) 20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.
Announcement not a prospectus
This announcement does not constitute a prospectus or prospectus equivalent document.
Private purchases
In accordance with normal
Rule 2.9 of the Code
For the purposes of Rule 2.9 of the Code, Yourgene confirms that, as at the date of this announcement, it has 3,193,466,515 Yourgene Shares in issue under the International Securities Identification Number GB00BN31ZD89. No Yourgene Shares are held by Yourgene in treasury.
If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the
APPENDIX
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
The following indicative timetable sets out expected dates for the implementation of the Scheme.
|
Event |
Time and/or date (2023)
|
|
Court Sanction Hearing |
7 September
|
|
Last day of dealings in, and for registration of transfers of, and disablement in CREST of, Yourgene Shares
|
7 September |
|
Scheme Record Time
|
|
|
Dealings in Yourgene Shares suspended
|
at or around |
|
Effective Date of the Scheme
|
8 September(1) |
|
Cancellation of admission of Yourgene Shares to trading on AIM
|
at or around |
|
Latest date for despatch of cheques and crediting of CREST for Consideration due under the Scheme
|
22 September |
|
Long Stop Date |
29 December(2) |
Notes:
(1) These dates and times are indicative only and will depend, among other things, on the date upon which: (i) the Conditions are satisfied or (if capable of waiver) waived; (ii) the Court sanctions the Scheme; and (iii) a copy of the Court Order is delivered to the Registrar of Companies.
(2) Following sanction of the Scheme by the Court, the Scheme will become Effective in accordance with its terms upon a copy of the Court Order being delivered to the Registrar of Companies. This is presently expected to occur within one Business Day after the date of the Sanction Hearing, subject to satisfaction or (where capable of waiver), waiver of the Conditions.
(3) This is the latest date by which the Scheme may become Effective unless Novacyt UK and Yourgene agree (and the Panel and, if required, the Court permit) a later date or if the Panel requires an extension to the Long Stop Date pending final determination of an issue under section 3(g) of Appendix 7 to the Takeover Code.
(4) The dates and times given are indicative only and are based on Yourgene's and Novacyt UK's current expectations and may be subject to change. If any of the expected times and/or dates above change (a) the revised times and/or dates will be notified to Yourgene Shareholders by announcement through a Regulatory Information Service, with such announcement being made available on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/ and on Novacyt's website at https://novacyt.com/investors/ and (b) if required by the Panel, Yourgene will send notice of the change(s) to Yourgene Shareholders and, for information only to Yourgene Share Plan Participants.
(5) All references to times are to
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE